Abstract
Premenstrual dysphoric disorder (PMDD) currently affects 3%-8% of menstruating women. The apparent biological pathogenesis of this controversial disorder makes psychopharmacologic treatment an efficacious intervention. Biopsychosocial aspects of premenstrual distress indicate that psychotherapy aimed at providing women with skills to alleviate their severe psychological and physical premenstrual symptoms may also be viable treatment options. This article reviews the factors associated with PMDD, as well as the efficacy of psychopharmacological and psychotherapeutic treatment options. Recommendations include the need for consensus regarding the use of the term PMDD, as well as the dissemination of accurate information about PMDD symptoms and treatment options.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
